Earlier this week, drugmaker Sanofi (SNY -1.44%) won approval for its multiple sclerosis treatment Lemtrada in the European Union. While the drug has yet to get the green light in the U.S., it is a key addition to Sanofi's multiple sclerosis lineup, which also includes the oral medication Aubagio. But can the company compete with Biogen (BIIB 2.34%) and its recently launched MS medication Tecfidera? Analysts David Williamson and Max Macaluso discuss this market in the following video.
Editor's note: At 6:36, the speaker incorrectly states that Sanofi had a partnership with Rigel Pharmaceuticals. The Fool regrets the error.
